Effect of anakinra in COVID-19 – Authors' reply

por Cavalli, Giulio, Dagna, Lorenzo
Publicado 2020

Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness

por Cavalli, Giulio, Dagna, Lorenzo
Publicado 2020

The right place for IL-1 inhibition in COVID-19

por Cavalli, Giulio, Dagna, Lorenzo
Publicado 2021

The course of action for effective anti-cytokine treatment in COVID-19

por Cavalli, Giulio, Dagna, Lorenzo
Publicado 2021

Anakinra Therapy for Non-cancer Inflammatory Diseases

por Cavalli, Giulio, Dinarello, Charles A.
Publicado 2018

Corrigendum: Anakinra Therapy for Non-cancer Inflammatory Diseases

por Cavalli, Giulio, Dinarello, Charles A.
Publicado 2019

Oncogene-Induced Senescence as a New Mechanism of Disease: The Paradigm of Erdheim–Chester Disease

por Cavalli, Giulio, Biavasco, Riccardo, Borgiani, Bruno, Dagna, Lorenzo
Publicado 2014

Anakinra for patients with COVID-19 – Authors' reply

por Cavalli, Giulio, Landoni, Giovanni, Zangrillo, Alberto, Dagna, Lorenzo
Publicado 2020

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply

por Cavalli, Giulio, Larcher, Alessandro, Tomelleri, Alessandro, Dagna, Lorenzo
Publicado 2021

Myocarditis: An Interleukin-1-Mediated Disease?

por De Luca, Giacomo, Cavalli, Giulio, Campochiaro, Corrado, Tresoldi, Moreno, Dagna, Lorenzo
Publicado 2018

Mavrilimumab for severe COVID-19 – Authors' reply

por De Luca, Giacomo, Cavalli, Giulio, Campochiaro, Corrado, Della-Torre, Emanuel, Dagna, Lorenzo
Publicado 2020

Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure

por Cavalli, Giulio, Foppoli, Marco, Cabrini, Luca, Dinarello, Charles A., Tresoldi, Moreno, Dagna, Lorenzo
Publicado 2017

Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?

por Benedetti, Francesco, Mazza, Mario, Cavalli, Giulio, Ciceri, Fabio, Dagna, Lorenzo, Rovere-Querini, Patrizia
Publicado 2020

Correction to: Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?

por Benedetti, Francesco, Mazza, Mario Gennaro, Cavalli, Giulio, Ciceri, Fabio, Dagna, Lorenzo, Rovere-Querini, Patrizia
Publicado 2021

Developing a framework for the implementation of recommendations for lifestyle factors for people with RMDs across Europe: assessment of current materials and implementation needs

por Rodríguez-Carrio, Javier, Cavalli, Giulio, Gwinnutt, James, Wieczorek, Maud, Guillemin, Francis, Verstappen, Suzanne M M
Publicado 2023

Cutaneous vasculitis following COVID-19 vaccination

por Cavalli, Giulio, Colafrancesco, Serena, De Luca, Giacomo, Rizzo, Nathalie, Priori, Roberta, Conti, Fabrizio, Dagna, Lorenzo
Publicado 2021

Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease

por Tomelleri, Alessandro, Cavalli, Giulio, De Luca, Giacomo, Campochiaro, Corrado, D’Aliberti, Teresa, Tresoldi, Moreno, Dagna, Lorenzo
Publicado 2018

Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease

por Cavalli, Giulio, Tomelleri, Alessandro, De Luca, Giacomo, Campochiaro, Corrado, Dinarello, Charles A., Baldissera, Elena, Dagna, Loreno
Publicado 2019

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease

por Cavalli, Giulio, Tomelleri, Alessandro, De Luca, Giacomo, Campochiaro, Corrado, Dinarello, Charles A., Baldissera, Elena, Dagna, Lorenzo
Publicado 2019

Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the...

por Cavalli, Giulio, Farina, Nicola, Campochiaro, Corrado, De Luca, Giacomo, Della-Torre, Emanuel, Tomelleri, Alessandro, Dagna, Lorenzo
Publicado 2020